UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Annals of oncology, 2014-02, Vol.25 (2), p.415-422

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

British journal of cancer, 2009-11, Vol.101 (9), p.1543-1548

2009

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Annals of oncology, 2013-09, Vol.24 (9), p.2382-2389

2013

Link zum Volltext

Verfügbarkeit prüfen

Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

Clinical and translational science, 2016-04, Vol.9 (2), p.63-73

2016

Link zum Volltext

Verfügbarkeit prüfen

L’anthropologie de communion du père Dumitru Staniloaë

Nouvelle revue théologique (Tournai), 2012-06, Vol.134 (3), p.409-423

Selaru, P. Sorin

2012

Link zum Volltext

Verfügbarkeit prüfen

A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension

European journal of ophthalmology, 2008-05, Vol.18 (3), p.408-416

2008

Link zum Volltext

Verfügbarkeit prüfen

1421P AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study

Annals of oncology, 2023-10, Vol.34, p.S811-S811

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

British journal of cancer, 2010-04, Vol.102 (8), p.1311-1311

2010

Link zum Volltext

Verfügbarkeit prüfen

Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

Circulation (New York, N.Y.), 2001-11, Vol.104 (20), p.2417-2423

2001

Link zum Volltext

Verfügbarkeit prüfen

9153 Safety and efficacy of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases

European journal of cancer supplements, 2009, Vol.7 (2), p.551-551

2009

Link zum Volltext

Verfügbarkeit prüfen

Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8077-8077

2009

Link zum Volltext

Verfügbarkeit prüfen

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial

The American heart journal, 2003, Vol.145 (1), p.179-186

2003

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.14522-14522

2008

Link zum Volltext

Verfügbarkeit prüfen

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

Circulation (New York, N.Y.), 2001-11, Vol.104 (20), p.2417

2001

Link zum Volltext

Verfügbarkeit prüfen

MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro

Oncogene, 2011-03, Vol.30 (13), p.1577-1585

2011

Link zum Volltext

Verfügbarkeit prüfen

Stimuli-Responsive Theragrippers for Chemomechanical Controlled Release

Angewandte Chemie (International ed.), 2014-07, Vol.53 (31), p.8045-8049

International ed. in English, 2014

Link zum Volltext

Verfügbarkeit prüfen

The miR-106b-25 Polycistron, Activated by Genomic Amplification, Functions as an Oncogene by Suppressing p21 and Bim

Gastroenterology (New York, N.Y. 1943), 2009-05, Vol.136 (5), p.1689-1700

2009

Link zum Volltext

Verfügbarkeit prüfen

MicroRNA‐21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3

Hepatology (Baltimore, Md.), 2009-05, Vol.49 (5), p.1595-1601

2009

Link zum Volltext

Verfügbarkeit prüfen

Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells

PloS one, 2009-11, Vol.4 (11), p.e8002

2009

Link zum Volltext

Verfügbarkeit prüfen

Non-Viral Gene Delivery to Hepatocellular Carcinoma via Intra-Arterial Injection

International journal of nanomedicine, 2023-01, Vol.18, p.2525-2537

2023

Link zum Volltext

Verfügbarkeit prüfen

Initial Clinical Outcomes Using Umbilical Cord-Derived Tissue Grafts to Repair Anovaginal Fistula

Diseases of the colon & rectum, 2023-02, Vol.66 (2), p.299

2023

Link zum Volltext

Verfügbarkeit prüfen

Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo

Science advances, 2020-10, Vol.6 (44)

2020

Link zum Volltext

Verfügbarkeit prüfen

A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (10), p.4112-4115

2009

Link zum Volltext

Verfügbarkeit prüfen

PSMA-Targeted PET Radiotracer [ 18 F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease

Clinical and experimental gastroenterology, 2023-01, Vol.16, p.237-247

2023

Link zum Volltext

Verfügbarkeit prüfen

Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma

PloS one, 2011-11, Vol.6 (11), p.e26799

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(69)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Humans
(30)
Life Sciences & Biomedicine
(28)
Male
(17)
Female
(16)
Biological And Medical Sciences
(15)
Medical Sciences
(15)
Middle Aged
(15)
Tumors
(15)
Adult
(14)
Oncology
(12)
Gastroenterology And Hepatology
(11)
Aged
(10)
Cell Line, Tumor
(9)
Gastroenterology. Liver. Pancreas. Abdomen
(9)
Reverse Transcriptase Polymerase Chain Reaction
(9)
Gastroenterology & Hepatology
(7)
Aged, 80 And Over
(6)
Animals
(6)
Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

L’anthropologie de communion du père Dumitru Staniloaë

A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension

1421P AI-powered intracranial tumor response predicts systemic progression with high concordance in endpoint evaluation in the phase III CROWN study

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

9153 Safety and efficacy of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases

Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial

A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro

Stimuli-Responsive Theragrippers for Chemomechanical Controlled Release

The miR-106b-25 Polycistron, Activated by Genomic Amplification, Functions as an Oncogene by Suppressing p21 and Bim

MicroRNA‐21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3

Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells

Non-Viral Gene Delivery to Hepatocellular Carcinoma via Intra-Arterial Injection

Initial Clinical Outcomes Using Umbilical Cord-Derived Tissue Grafts to Repair Anovaginal Fistula

Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo

A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus

PSMA-Targeted PET Radiotracer [ 18 F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease

Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma

Suchergebnisse filtern